BenchSci, a leading provider of AI software for biopharma research and development, renewed its two-year contract with Merck, known as MSD outside of the United States and Canada. The renewed agreement supports Merck’s efforts to integrate AI more deeply into its scientific workflows. With ongoing access to ASCEND, scientists can more easily evaluate evidence and surface insights that inform early development decisions. BenchSci’s ASCEND is the first neurosymbolic AI platform built to help...